Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
Recruiting now · Phase 2
Conditions studied: Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy, Safety
In brief
Concurrent chemoradiotherapy (cCRT) is the standard treatment for patients with negative epidermal growth factor receptor (EGFR)-mutated unresectable locally advanced non-small cell lung cancer (LA-NSCLC). However, parts of patients only receive sequential chemoradiotherapy (sCRT) due to various reasons. This phase II study aimed to improve the outcomes of patients receiving sCRT by combining anti-angiogenesis therapy (Anlotinib) during radiotherapy course.We hypothesize that the combination of radiotherapy with anlotinib could improve the 2-year PFS rate from 35% with sCRT to 50. The accrual target was 44 patients.
Key facts
- Study ID
- NCT07037680
- Run by
- JIANYANG WANG
- People needed
- 44
- Starts
- 2024-01-01
- Expected to finish
- 2026-06-30
- Last updated by the study team
- 2025-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- ≥18 years old with no restrictions on sex;
- Peripheral tumor, or central lung cancer with non-squamous tissue or a mixed tissue with less than 50% squamous carcinoma;
- Eastern cooperative oncology group (ECOG) score ≤2 was required;
- Received systemic chemotherapy or combined chemotherapy and immumitherapy for ≥ 4 weeks without progression;
- .No cavity inside the tumor, and located ≥ 1 cm of the main pulmonary artery trunk;
- No symptoms of hemoptysis;
- Adequate hepatic and renal functions with a negative urine protein;
- Expected survival of more than 6 months.
You may not qualify if…
- currently receiving treatment for malignancies at other sites, except for curable non-melanoma skin cancer and cervical carcinoma in situ;
- previous malignancy within five years;
- thoracic radiotherapy history, hemoptysis, myocardial infarction or cerebrovascular accident within three months;
- uncontrolled or active pulmonary inflammation;
- participated in other clinical trials;
- Pregnant women.
Where it is running
- Department of Radiation Oncology,Cancer Institute and Hospital,Chinese — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.